Lung cancer is the leading cause of cancer death in the United States, claiming more lives each year than breast, colorectal, and prostate cancers combined. For 2026, the American Cancer Society estimates approximately 229,410 new lung cancer diagnoses and 124,990 deaths in the U.S. Encouragingly, both incidence and mortality have been trending downward for years as smoking rates fall and treatment improves. The landscape of lung cancer care has transformed dramatically over the past decade — biomarker-guided targeted therapies, immunotherapy, and better screening are reshaping survival statistics in ways that would have seemed impossible a generation ago. Understanding your risk, recognizing early symptoms, and knowing the current treatment options can meaningfully improve outcomes. For an overview of major health conditions, visit our medical conditions guide.
Quick summary. Lung cancer is common and serious, but it is no longer uniformly fatal. Most cases are NSCLC; SCLC is less common but more aggressive. If you are 50–80 with a significant smoking history, ask about low-dose CT screening — it is the only screening test proven to lower lung cancer deaths. A cough that won’t quit, coughing up blood, unexplained weight loss, chest pain, or new shortness of breath deserve prompt evaluation. Modern treatment is guided by molecular (biomarker) testing and is highly individualized. This article is general education, not medical advice — decisions about screening and treatment should be made with your own clinician.
Types of Lung Cancer
Non-Small Cell Lung Cancer (NSCLC)
NSCLC accounts for approximately 80 to 85 percent of all lung cancers. It includes three major subtypes. Adenocarcinoma, the most common, typically arises in the outer regions of the lung and is the type most frequently seen in people who have never smoked and in younger patients. Squamous cell carcinoma tends to develop in the central airways and is strongly associated with smoking. Large cell carcinoma can appear anywhere in the lung and tends to grow and spread quickly. These subtypes matter because they respond differently to treatment and may harbor distinct genetic mutations that can be targeted with precision therapies.
Small Cell Lung Cancer (SCLC)
SCLC accounts for 10 to 15 percent of lung cancers and is almost exclusively caused by smoking. According to the National Cancer Institute, SCLC is the more aggressive form — it grows rapidly, spreads early, and is frequently diagnosed after it has already metastasized. It is initially very responsive to chemotherapy and radiation, but recurrence is common. SCLC is staged simply as “limited stage” (confined to one side of the chest) or “extensive stage” (spread beyond one hemithorax). The addition of immunotherapy to first-line chemotherapy has become standard for extensive-stage disease and has modestly improved survival.
Other Types
Less common lung malignancies include carcinoid tumors (slow-growing neuroendocrine tumors), lymphomas of the lung, and sarcomas. The lung is also a common site for metastases from cancers originating elsewhere — breast, colon, kidney, and melanoma frequently spread to the lungs. Distinguishing primary lung cancer from metastatic disease is critical for treatment planning, and it is one reason biopsy and molecular testing are so important before treatment begins.
Risk Factors
Cigarette smoking is responsible for approximately 80 to 90 percent of lung cancer deaths. The risk increases with the number of cigarettes smoked per day and the number of years of smoking, often quantified as “pack-years” (packs per day multiplied by years smoked). According to the CDC, smokers are 15 to 30 times more likely to develop lung cancer than non-smokers. Quitting reduces risk significantly over time, though it never returns fully to the level of a never-smoker — which is why former smokers remain eligible for screening for years after quitting.
Secondhand smoke exposure causes thousands of lung cancer deaths per year among non-smokers in the United States. Radon — a naturally occurring radioactive gas that can accumulate in homes — is the second leading cause of lung cancer overall and the leading cause among people who have never smoked. The EPA estimates radon causes roughly 21,000 lung cancer deaths annually. Home radon testing is inexpensive and widely available, and mitigation is straightforward when levels are elevated.
Occupational exposures to asbestos, arsenic, chromium, nickel, and diesel exhaust are established risk factors. Air pollution, previous radiation therapy to the chest, and a personal or family history of lung cancer also increase risk. Notably, 10 to 20 percent of lung cancers occur in people who have never smoked — a reality that challenges the persistent stigma associating lung cancer exclusively with smoking, and one reason emerging symptoms should never be dismissed simply because someone doesn’t smoke.
Symptoms and Early Warning Signs
Lung cancer is notoriously difficult to detect early because the interior lung tissue has no pain receptors, and early-stage tumors may produce no symptoms at all. When symptoms do appear, they often overlap with more common conditions, leading to delays in diagnosis. The Mayo Clinic identifies the following as common lung cancer symptoms: a new cough that doesn’t go away, changes in a chronic cough, coughing up blood (even a small amount), shortness of breath, chest pain that worsens with deep breathing or coughing, hoarseness, unexplained weight loss, bone pain, and headache.
Red flags — get checked promptly. See a doctor without delay if you notice any of these, especially as a current or former smoker: coughing up blood or rust-colored sputum; a cough that persists beyond two to three weeks or is worsening; unexplained weight loss; ongoing chest, shoulder, or back pain; new or worsening shortness of breath; hoarseness; or recurrent chest infections. Call 911 for coughing up a large amount of blood, sudden severe shortness of breath, sudden severe chest pain, fainting, confusion or sudden neurological changes, or signs of a blood clot (sudden leg swelling with breathlessness). These can signal a life-threatening complication and should not wait.
Advanced lung cancer can cause a wide range of additional symptoms depending on where it has spread. Brain metastases may cause headaches, seizures, or neurological deficits. Bone metastases cause pain, often in the back, hips, or ribs. Liver metastases can cause jaundice and abdominal pain. Paraneoplastic syndromes — metabolic disturbances caused by substances produced by the tumor — can cause hypercalcemia, Cushing syndrome, or neurological problems such as a distinctive muscle-weakness syndrome. These varied presentations are part of why lung cancer is sometimes diagnosed only after it has spread.
Screening: Catching It Early
Low-dose computed tomography (LDCT) screening is the only proven method for early lung cancer detection and was shown to reduce lung cancer mortality by about 20 percent in the National Lung Screening Trial. The U.S. Preventive Services Task Force (USPSTF) recommends annual LDCT screening for adults aged 50 to 80 who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. This guidance, broadened in 2021 to include younger and lighter smokers, remains current.
Despite strong evidence supporting screening, uptake remains low — only a small minority of eligible Americans get screened. Barriers include lack of awareness, providers not discussing screening, access issues, and concerns about cost and false positives. Under the Affordable Care Act, lung cancer screening is covered without cost-sharing for eligible individuals in most private plans and Medicare, provided you meet the age and smoking-history criteria; it is always reasonable to confirm eligibility and coverage before scheduling.
Screening is not without limitations. False positives are common — most lung nodules found on LDCT are benign and require follow-up imaging, which can cause anxiety and additional testing. Overdiagnosis (finding cancers that would never have caused harm) is a concern, though it appears less significant than with some other cancer screenings. For the eligible population the benefits of screening outweigh these risks, but the decision should involve a shared discussion about the potential benefits, harms, and the individual’s preferences. Screening is meant to complement, not replace, quitting smoking.
Staging
Staging determines how far the cancer has spread and is the most important factor in treatment planning and prognosis. NSCLC uses the TNM staging system: T describes the size and extent of the primary tumor, N describes spread to regional lymph nodes, and M indicates the presence or absence of distant metastasis. These are combined into overall stages I through IV.
Stage I lung cancer is confined to the lung without lymph node involvement. Stage II involves larger tumors or limited lymph node spread within the lung. Stage III indicates more extensive lymph node involvement, including mediastinal nodes. Stage IV means the cancer has spread to distant sites. Survival varies dramatically by stage. Using SEER data reported by the American Cancer Society, 5-year relative survival for NSCLC is approximately 67 percent when localized, about 40 percent when it has spread regionally, and roughly 12 percent when distant — about 32 percent across all stages combined. For small cell lung cancer, the corresponding figures are lower (roughly 34 percent localized, 20 percent regional, 4 percent distant, and about 9 percent overall). These are population averages based on people diagnosed in prior years and do not predict any individual’s outcome; survival for many patients continues to improve as newer therapies reach the clinic.
Staging workup typically includes CT of the chest and abdomen, a PET scan (which detects metabolic activity in cancer cells throughout the body), brain MRI (since lung cancer frequently metastasizes to the brain), and often minimally invasive procedures such as endobronchial ultrasound-guided biopsy or mediastinoscopy to sample lymph nodes. Accurate staging is essential because it determines whether treatment is aimed at cure or at controlling the disease.
Treatment Options
Lung cancer treatment is highly individualized and increasingly guided by the tumor’s molecular profile. It is always directed by an oncology team, and the summaries below describe categories of therapy rather than specific doses or regimens — those depend on your cancer’s biology, stage, and overall health.
Surgery
Surgery offers the best chance of cure for early-stage NSCLC (stages I and II and select stage III). The standard procedure is lobectomy — removal of the entire lobe containing the tumor. For smaller tumors or patients who cannot tolerate lobectomy, segmentectomy or wedge resection (removing a smaller portion of lung) may be performed. Data from the JCOG0802 and CALGB 140503 trials have shown that sublobar resection can be non-inferior to lobectomy for small peripheral tumors, expanding options for lung-sparing surgery. Pneumonectomy (removal of an entire lung) is rarely performed today. Many operations are now done with minimally invasive video-assisted or robotic techniques, shortening recovery.
Radiation Therapy
Radiation therapy uses high-energy beams to destroy cancer cells. Stereotactic body radiation therapy (SBRT) delivers highly focused, high-dose radiation to small tumors in a few sessions and achieves local control rates comparable to surgery in early-stage patients who are not surgical candidates. Conventional radiation therapy is used for locally advanced disease, often combined with chemotherapy, and consolidation immunotherapy after chemoradiation has become standard for many stage III patients. Radiation also plays a valuable role in palliating symptoms from metastatic disease, including brain metastases and bone pain.
Systemic Therapies
Chemotherapy remains part of treatment for advanced lung cancer, often using platinum-based doublets (cisplatin or carboplatin with a second agent). But the real revolution has been in targeted therapy and immunotherapy. Molecular profiling — biomarker testing for alterations in EGFR, ALK, ROS1, BRAF, KRAS (including KRAS G12C), MET, RET, NTRK, HER2, and other genes — identifies patients who can benefit from targeted drugs that block specific cancer-driving pathways. For example, EGFR inhibitors such as osimertinib have transformed outcomes for EGFR-mutant NSCLC and are now used not only in advanced disease but also after surgery in select cases; ALK inhibitors, KRAS G12C inhibitors, and other targeted agents have similarly expanded options. Comprehensive biomarker testing is now considered essential before starting first-line therapy for advanced NSCLC.
Immunotherapy — particularly immune checkpoint inhibitors such as pembrolizumab, nivolumab, and atezolizumab — has become standard treatment for many lung cancer patients. These drugs release the brakes on the immune system, enabling it to recognize and attack cancer cells. Immunotherapy is now used not only for advanced disease but also in the perioperative setting (before and/or after surgery) for eligible patients with resectable NSCLC, which has improved the odds of long-term disease control. According to the National Cancer Institute, immunotherapy has produced durable responses in some patients with advanced lung cancer, with a meaningful subset surviving five years or longer — outcomes that were exceptionally rare before these drugs became available. Newer approaches, including antibody-drug conjugates and bispecific antibodies, continue to enter practice through clinical trials and approvals. Which therapy is right depends on tumor biology and is a decision for your oncology team.
Living With Lung Cancer: Support and Quality of Life
A lung cancer diagnosis affects every dimension of life — physical, emotional, financial, and social. Integrating palliative care early in the treatment course has been shown to improve quality of life and, in some studies, even survival. Palliative care is not the same as hospice; it focuses on symptom management, emotional support, and help with treatment decisions alongside curative-intent therapy.
Pulmonary rehabilitation, nutritional support, pain management, and psychological counseling are all important components of comprehensive lung cancer care. The financial burden can be substantial — understanding healthcare costs and insurance coverage for cancer treatment helps patients and families plan and access available resources, including patient assistance and copay programs offered by manufacturers and nonprofit foundations.
Support groups, both in-person and online, provide connection with others facing similar challenges. Organizations like the American Lung Association and LUNGevity Foundation offer resources, support networks, and advocacy for lung cancer patients and their families. Addressing the stigma that surrounds lung cancer — the assumption that patients “brought it on themselves” — is an ongoing effort that benefits all patients regardless of their smoking history.
Frequently Asked Questions
Can non-smokers get lung cancer?
Yes. Approximately 10 to 20 percent of lung cancers in the United States occur in people who have never smoked. Radon exposure, secondhand smoke, occupational carcinogens, air pollution, and genetic factors can all cause lung cancer in non-smokers. Lung cancer in never-smokers is more commonly adenocarcinoma and is more likely to harbor targetable genetic alterations like EGFR or ALK, which can be treated with effective targeted therapies. That is one reason biomarker testing is recommended for essentially all patients with advanced NSCLC.
What are the first signs of lung cancer?
Early lung cancer often has no symptoms, which is why screening matters for high-risk individuals. When symptoms do appear, a persistent new cough, coughing up blood (even small amounts), unexplained shortness of breath, and unintentional weight loss are among the most common early presentations. Any cough lasting more than two to three weeks, particularly in a current or former smoker, warrants medical evaluation.
How effective is lung cancer screening?
The National Lung Screening Trial demonstrated about a 20 percent reduction in lung cancer mortality with annual LDCT screening compared with chest X-ray. The NELSON trial in Europe showed a similar or larger benefit. Screening is most effective when done consistently in the eligible population and followed by timely workup of abnormal findings. The main limitation is a high false-positive rate, which leads to additional imaging and, occasionally, unnecessary invasive procedures — a trade-off worth discussing with your doctor.
What is the survival rate for lung cancer?
Overall 5-year survival has been steadily improving thanks to earlier detection and better treatments. Stage matters enormously: for NSCLC, localized disease has a 5-year relative survival around 67 percent, while distant (stage IV) disease is closer to 12 percent, with all stages combined near 32 percent. Small cell lung cancer has lower survival overall (about 9 percent across all stages). Individual prognosis depends on many factors, including stage, tumor biology, molecular markers, overall health, and response to treatment, so these averages should not be read as a personal prediction.
Is immunotherapy available for all lung cancer patients?
Not everyone is a candidate. Checkpoint inhibitors are most commonly used for NSCLC — particularly tumors with high PD-L1 expression or those without a targetable driver mutation — and now also in the perioperative setting for some resectable cancers. Some combinations are approved regardless of PD-L1 status, and immunotherapy is added to first-line chemotherapy for extensive-stage SCLC. Patients with certain autoimmune conditions or those on immunosuppressive medications may not be suitable candidates. Molecular profiling of the tumor is essential to determine the best approach, which your oncologist will individualize.
Does quitting smoking still help after a lung cancer diagnosis?
Yes. Quitting smoking after diagnosis is associated with better treatment tolerance, fewer complications, and improved outcomes, in addition to reducing the risk of other smoking-related diseases. It is never too late to benefit, and your care team can connect you with cessation support.
What to Do Next
If you’re a current or former smoker aged 50 to 80 with a 20 pack-year history, ask your doctor about LDCT screening. This single conversation could save your life by catching cancer at a stage when cure is possible. If you’re currently smoking, quitting is still the most impactful thing you can do for your lung cancer risk — and your overall health. Effective cessation resources include the national quitline (1-800-QUIT-NOW), nicotine replacement therapy, and prescription medications; your clinician can help you choose.
If you’ve been diagnosed with lung cancer, ensure that your tumor has undergone comprehensive molecular (biomarker) profiling before treatment decisions are finalized. The specific mutations and biomarkers in your cancer can open doors to targeted therapies and immunotherapies that outperform traditional chemotherapy for many patients. Seek care at a center experienced in lung cancer — multidisciplinary tumor boards that include thoracic surgeons, medical oncologists, radiation oncologists, and pulmonologists provide the most informed recommendations, and a second opinion is always reasonable.
Lung cancer remains a formidable disease, but it is no longer the uniformly fatal diagnosis it once was. Advances in screening, molecular medicine, and immunotherapy are rewriting the story — and staying informed about your options is the first step toward the best possible outcome. This guide is educational and not a substitute for personalized advice from your own healthcare providers.